There is still no genetic variant that can be used as a biomarker to predict the therapeutic response in patients with asthma, although the LTBP1 was the most consistently associated gene in a favorable ICS response among asthma patients, and genetic variations in glucocorticoid-induced transcript 1 genes (GLCCI1) were linked with decreased lung function in subjects treated with ICS. The gene discussed is GLCCI1; the disease is asthma.